Shots:

• The approval is based on two P-III international studies that evaluate cosentyx in pediatric patients aged 6 to <18 yrs. with mod. to sev. PsO who are candidates for systemic therapy or phototherapy
• The results showed that the therapy is safe and effective for children and adults with PsO. Additionally- therapy has supported the 5yrs. sustained efficacy and safety data across several inflammatory conditions
• The company has filed for regulatory approval in the US and EU for cosentyx to treat JPsA and ERA & plans to expand the therapy to 10 indications over the next 10 yrs. The therapy is also approved in China for adults with moderate-to-severe PsO & ankylosing spondylitis

  Ref: Novartis | Image: Novartis